New York City, NY -- (SBWIRE) -- 01/13/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), Generex Biotechnology Corporation (OTCMKTS:GNBT), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) gained 62.86%, trading on 38.12 million shares, to end the trade at $1.14. The stock changed hands in a range of $0.78 to $1.19, bringing its market capitalization to about $167.26 million. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.28 and was moved to the maximum level of $1.19. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials.
For How Long RNN Gloss will Attract Investors? Find out via this report
Generex Biotechnology Corporation (OTCMKTS:GNBT) added 30.81%, to complete the trading session at $0.0484, with a total volume of 136.90 million shares. The stock, on average, trades on a volume of 3.18 million shares. It floated in a range of $0.04 to $0.06 during the last trading session, with a beta value of 2.12. Its market capitalization now moved to about $28.09 million. In the past 52 weeks, the share price has not declined below $0.02 and above $0.07. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
Will GNBT Continue To Move Higher? Find Out Here
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) recorded a gain of 61.61% and was in a range of $373.00-$497.00 before closing at $445.83. The stock completed the day with a total volume of 5.98 million shares, versus an average volume of 652,499 shares. The share price hit its 52-week low of $30.38 and $497.00 was the best price. Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company’s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid.
Why Should Investors Buy ICPT After The Recent Gain? Just Go Here and Find Out
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) added 45.41%, bringing its market capitalization around $222.58 million. The share price, after opening at $13.00,, made a high of $15.67 and hovered above $12.25 to end the day at $14.25. The total number of shares that changed hands during the session was 8.79 million shares, as compared to average trading volume of 11,421 shares. Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease.
What was the Moving Force behind CNAT on Bullish Run? Read This Research Report
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)